Regeneron Pharmaceuticals

Open: 838.87 Close: 836.07 Change: -2.8

You'll be sorry if you don't use an AI to decide whether to invest in Regeneron Pharmaceuticals.

Are looking for the most relevant information about Regeneron Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Regeneron Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, Inc, stock, REGN, USD, rise, and the most common words in the summary are: regeneron, stock, pharmaceutical, market, job, inc, regn, . One of the sentences in the summary was: The Score for REGN is 65, which is 30%.. Other searches …

Concept Map

Semantic Network

Stock Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The company's products include EYLEA injection to treat neovascular age-related macular degeneration.

Today's Summary

Regeneron Pharmaceuticals Inc. stock rises wed Wednesday, still underperforms market. IRS notifies Microsoft it owes an additional $29 billion in back taxes. The Score for REGN is 65, which is 30%.

Today's News

Regeneron Pharmaceuticals Inc. stock rises wed Wednesday, still underperforms market - marketwatch.com. IRS notifies Microsoft it owes an additional $29 billion in back taxes. The current Regeneron Pharmaceuticals [ REGN ] share price is $834.96. The Score for REGN is 65, which is 30% above its historic median score. Regeneron Pharmaceuticals (NASDAQ:REGN) Current Price: $835.71 52w High/Low: $668.00 - 847.5 Market Cap: 90.6B Price/Earnings: 22.08 Dividend Yield: - Volume/Average: 307K-406K Listed in 1991. Latest SEC filings for Regeneron Pharmaceuticals, Inc. (regn) Follow $ 836.07 1.11 ( +0.13% ) 4:00 PM 10/11/23 NASDAQ | $USD | $ USD | Post-Market: $836. Regeneron Pharmaceuticals stock opened at $836.57 on Monday. The company last released its quarterly earnings results on Thursday, August 3rd.

Stock Profile

"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York."

Keywords

The game is changing. There is a new strategy to evaluate Regeneron Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, Inc, stock, REGN, USD, rise, and the most common words in the summary are: regeneron, stock, pharmaceutical, market, job, inc, regn, . One of the sentences in the summary was: The Score for REGN is 65, which is 30%.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #regeneron #stock #pharmaceutical #market #job #inc #regn.